Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Post Amalgamation

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 04, 2021 9:55am

130 Views

Post# 33122570

RE:Post Amalgamation

Stoxxhp wrote: I would bet there will be a significant relief rally once amalgamation is announced, there may be some reactive volatility immediately after, however once it settles I suspect a strong and steady climb.
In the markets, and probably in general life, the only thing worse than bad news is uncertainty.

Stick to the facts and fundamentals, everything else is just noise

It all seems to be coming together for P3 initiation. Makes sense.

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 6, 2024